A Multicenter Comparison of 2 Point-of-Care Activated Clotting Time Test Systems

被引：0
|
作者：
Kemna, Evelien W. M. [1 ,2 ]
Schellings, Mark W. M. [3 ]
Vlachojannis, Georgios J. [4 ]
Falter, Florian [5 ]
Milane-Santman, Antoinette [6 ]
Hesselink, Tim [6 ]
Scholten, Marcoen [6 ]
Krabbe, Johannes G. [1 ,2 ]
机构：
[1] Med Lab Oost Nederland, Medlon, Enschede, Netherlands
[2] Med Spectrum Twente, MST, Enschede, Netherlands
[3] Maasstad Hosp, Dept Clin Chem, Rotterdam, Netherlands
[4] Maasstad Hosp Rotterdam, Dept Cardiol, Rotterdam, Netherlands
[5] Papworth Hosp, Dept Anaesthesia & Intens Care, Cambridge, England
[6] Thorax Ctr Twente, Med Spectrum Twente, MST, Enschede, Netherlands
来源：
JOURNAL OF APPLIED LABORATORY MEDICINE | 2019年 / 4卷 / 03期
关键词：
D O I：
10.1373/jalm.2019.029066
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：468 / 470
页数：3
相关论文
共 50 条
  • [31] Point-of-care test for cervical cancer in LMICs
    Mohammed, Sulma I.
    Ren, Wen
    Flowers, Lisa
    Rajwa, Bartek
    Chibwesha, Carla J.
    Parham, Groesbeck P.
    Irudayaraj, Joseph M. K.
    ONCOTARGET, 2016, 7 (14) : 18787 - 18797
  • [32] Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time:: in vitro comparison of two different point of care devices
    Dalbert, S
    Ganter, MT
    Furrer, L
    Klaghofer, R
    Zollinger, A
    Hofer, CK
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2006, 50 (04) : 461 - 468
  • [33] Assessment of dabigatran activity using the activated clotting time assay with concomitant heparin in vitro: comparison of two different point of care tests
    Van Ryn, J.
    Schurer, J.
    Clemens, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 555 - 556
  • [34] Agreement of point-of-care prothrombin and activated partial thromboplastin time in dogs with a reference laboratory
    Yang, W.
    Hosgood, G.
    Luobikis, K.
    Paul, A.
    AUSTRALIAN VETERINARY JOURNAL, 2018, 96 (10) : 379 - 384
  • [35] Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers
    Michael P. Ero
    Nathaniel R. Harvey
    Jack L. Harbert
    James W. Janc
    Kay H. Chin
    Steven L. Barriere
    Journal of Thrombosis and Thrombolysis, 2014, 38 : 235 - 240
  • [36] Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers
    Ero, Michael P.
    Harvey, Nathaniel R.
    Harbert, Jack L.
    Janc, James W.
    Chin, Kay H.
    Barriere, Steven L.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 38 (02) : 235 - 240
  • [37] Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability
    Daniel Dirkmann
    Elisabeth Nagy
    Martin W. Britten
    Jürgen Peters
    BMC Anesthesiology, 19
  • [38] Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability
    Dirkmann, Daniel
    Nagy, Elisabeth
    Britten, Martin W.
    Peters, Juergen
    BMC ANESTHESIOLOGY, 2019, 19 (01)
  • [39] Greater Variation in the Point of Care Activated Clotting Time During Ablation Procedures is Observed at Therapeutic Values
    Dresen, William F.
    Schmidt, Paula
    Nagarajan, Vijai
    Murphy, Michele A.
    Mealor, Augustus E.
    Camnitz, Will M.
    Darby, Andrew E.
    Malhotra, Rohit
    Bilchick, Kenneth C.
    Mason, Pamela K.
    Mangrum, J. M.
    DiMarco, John P.
    Ferguson, John D.
    CIRCULATION, 2016, 134
  • [40] A QUALITY-CONTROL SYSTEM FOR THE ACTIVATED CLOTTING TIME TEST
    SEDOR, FA
    MAYO, E
    KIRVAN, KE
    CLINICAL CHEMISTRY, 1987, 33 (07) : 1261 - 1261
12345